Exploring the role of chemerin in skeletal muscle phenotype in those with kidney disease
We report that chemerin is a uraemic toxin in those with CKD and may contribute to poorer muscle quality in these people. Chemerin can moderate indicators of inflammation within HDMCs via the activation of CMKLR1 and warrants further investigations to validate it as a potential new therapeutic target to alleviate the symptoms of uraemic sarcopenia.
Authors
- Hannah Young (ORCID: https://orcid.org/0000-0002-4249-9060)
- Thomas J. Wilkinson (ORCID: https://orcid.org/0000-0002-7855-7752)
- Daniel S. March (ORCID: https://orcid.org/0000-0002-1468-6918)
- Amelia Abbott
- Matthew Denniff
- Robert U. Ashford
- James Burton
- Luke A Baker
- Daniella Cardoso
- Matthew Graham-Brown
- Rosie Billany
- Alice C. Smith
- Patrick Highton
- Joao Viana
- Nicola Parker
- Emma L. Watson
Institutions
- University of Leicester (GB)
- University Hospitals of Leicester NHS Trust (GB)
- National Institute for Health and Care Research (GB)
- Health and Human Development (2HD) Research Network (CM)
- NIHR Leicester Biomedical Research Centre (GB)
- Instituto Superior da Maia (PT)
Publication Details
- Journal
- Translational research
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1016/j.trsl.2026.02.009
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00